BR112014014452A2 - derivados de pirazolpiridina, processo de preparação dos mesmos e uso terapêutico dos mesmos - Google Patents

derivados de pirazolpiridina, processo de preparação dos mesmos e uso terapêutico dos mesmos

Info

Publication number
BR112014014452A2
BR112014014452A2 BR112014014452A BR112014014452A BR112014014452A2 BR 112014014452 A2 BR112014014452 A2 BR 112014014452A2 BR 112014014452 A BR112014014452 A BR 112014014452A BR 112014014452 A BR112014014452 A BR 112014014452A BR 112014014452 A2 BR112014014452 A2 BR 112014014452A2
Authority
BR
Brazil
Prior art keywords
derivatives
therapeutic use
pyrazolpyridine
preparation process
preparing
Prior art date
Application number
BR112014014452A
Other languages
English (en)
Inventor
Alcouffe Chantal
Mauger Jacques
Bjegarde Kirsten
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR112014014452A2 publication Critical patent/BR112014014452A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

resumo patente de invenção: "derivados de pirazolpiridina, processo de preparação dos mesmos e uso terapêutico dos mesmos". a invenção refere-se a derivados de pirazolpirimidina inibitórios de fgf de fórmula geral (i) a um processo para preparar os mesmos e ao uso terapêutico dos mesmos.
BR112014014452A 2011-12-14 2012-12-13 derivados de pirazolpiridina, processo de preparação dos mesmos e uso terapêutico dos mesmos BR112014014452A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1161589A FR2984325A1 (fr) 2011-12-14 2011-12-14 Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
PCT/EP2012/075328 WO2013087744A1 (en) 2011-12-14 2012-12-13 Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof

Publications (1)

Publication Number Publication Date
BR112014014452A2 true BR112014014452A2 (pt) 2017-06-13

Family

ID=47458918

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014014452A BR112014014452A2 (pt) 2011-12-14 2012-12-13 derivados de pirazolpiridina, processo de preparação dos mesmos e uso terapêutico dos mesmos

Country Status (23)

Country Link
US (2) US20140350006A1 (pt)
EP (1) EP2791137B1 (pt)
JP (2) JP6214551B2 (pt)
KR (1) KR102012058B1 (pt)
CN (2) CN106317056B (pt)
AU (1) AU2012351712B2 (pt)
BR (1) BR112014014452A2 (pt)
CA (1) CA2857749A1 (pt)
CL (1) CL2014001539A1 (pt)
CO (1) CO7000778A2 (pt)
DK (1) DK2791137T3 (pt)
EA (1) EA027421B1 (pt)
ES (1) ES2719444T3 (pt)
FR (1) FR2984325A1 (pt)
HK (1) HK1198442A1 (pt)
IL (1) IL232906A (pt)
MA (1) MA35841B1 (pt)
MX (1) MX358422B (pt)
PH (1) PH12014501258A1 (pt)
PL (1) PL2791137T3 (pt)
PT (1) PT2791137T (pt)
SG (2) SG10201510204QA (pt)
WO (1) WO2013087744A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2984325A1 (fr) * 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
US10138235B2 (en) 2011-12-14 2018-11-27 Sanofi Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof
CA2898415A1 (en) 2013-01-16 2014-07-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
PL2970265T3 (pl) 2013-03-15 2018-11-30 Plexxikon Inc. Heterocykliczne związki i ich zastosowania
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
EA030558B1 (ru) * 2013-06-14 2018-08-31 Санофи Применение производных пиразолопиридина для лечения рака мочевого пузыря
RU2658821C1 (ru) 2014-08-18 2018-06-25 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Соль моноциклического производного пиридина и ее кристалл
WO2017053604A1 (en) * 2015-09-23 2017-03-30 The Regents Of The University Of California Potent antiviral pyrazolopyridine compounds
PL3481859T3 (pl) 2016-07-07 2022-07-11 Pfizer Inc. Rozpuszczalne polipeptydy receptora 3 czynnika wzrostu fibroblastów (sfgfr3) i ich zastosowania
CA3079029A1 (en) 2017-10-13 2019-04-18 Plexxikon Inc. Solid forms of a compound for modulating kinases
WO2019158731A1 (en) * 2018-02-16 2019-08-22 Ucb Biopharma Sprl Pharmaceutical 6,5 heterobicyclic ring derivatives
MX2020008610A (es) 2018-03-28 2020-09-21 Eisai R&D Man Co Ltd Agente terapeutico para carcinoma hepatocelular.
CN108774224B (zh) * 2018-04-23 2020-10-30 浙江大学 吡唑并[3,4-b]吡啶类化合物及其制备方法和应用
CN110833556A (zh) * 2018-08-15 2020-02-25 广西梧州制药（集团）股份有限公司 吡唑并嘧啶衍生物在治疗肝纤维化的用途
WO2020178316A1 (en) * 2019-03-05 2020-09-10 Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.P.A. 5- or 7-azaindazoles as beta-lactamase inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7855205B2 (en) * 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
DE102004061288A1 (de) * 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
BRPI0610828A2 (pt) * 2005-05-16 2010-07-27 Irm Llc compostos e composições como inibidores de proteìna quinase
WO2006130673A1 (en) * 2005-05-31 2006-12-07 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
FR2889526B1 (fr) * 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
MX2009002010A (es) * 2006-09-06 2009-03-05 Hoffmann La Roche Derivados de heteroarilo como inhibidores de la proteina cinasa.
KR20090031122A (ko) * 2007-09-21 2009-03-25 주식회사 중외제약 인다졸 골격을 함유하는 화합물, 이의 제조방법 및 상기화합물을 함유하는 약제학적 조성물
ES2399945T3 (es) * 2007-11-30 2013-04-04 Pfizer Limited Agonistas novedosos de los receptores de glucocorticoides
AU2009335016A1 (en) * 2008-12-30 2011-08-18 Arqule, Inc. Substituted pyrazolo [3, 4-b] pyridine compounds
FR2951172B1 (fr) * 2009-10-13 2014-09-26 Pf Medicament Derives pyrazolopyridines en tant qu'agent anticancereux
JP5822844B2 (ja) * 2009-12-21 2015-11-24 サミュメッド リミテッド ライアビリティ カンパニー １Ｈ−ピラゾロ［３，４−ｂ］ピリジンおよびその治療的使用
WO2012019954A1 (en) * 2010-08-12 2012-02-16 Evotec (Uk) Ltd. Pyrazolopyridine compounds as pde10a inhibitors
FR2984325A1 (fr) * 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique

Also Published As

Publication number Publication date
IL232906A (en) 2017-12-31
JP6214551B2 (ja) 2017-10-18
IL232906A0 (en) 2014-08-03
CN104114555A (zh) 2014-10-22
FR2984325A1 (fr) 2013-06-21
US20170231998A1 (en) 2017-08-17
CA2857749A1 (en) 2013-06-20
CN106317056A (zh) 2017-01-11
WO2013087744A1 (en) 2013-06-20
PT2791137T (pt) 2019-05-08
EP2791137B1 (en) 2019-01-23
PL2791137T3 (pl) 2019-07-31
HK1198442A1 (en) 2015-04-24
ES2719444T3 (es) 2019-07-10
MX358422B (es) 2018-08-20
DK2791137T3 (en) 2019-04-23
CO7000778A2 (es) 2014-07-21
CL2014001539A1 (es) 2014-10-17
CN106317056B (zh) 2020-06-23
JP2017206544A (ja) 2017-11-24
EP2791137A1 (en) 2014-10-22
AU2012351712A1 (en) 2014-07-10
PH12014501258A1 (en) 2014-09-08
AU2012351712B2 (en) 2017-08-31
JP2015500318A (ja) 2015-01-05
MA35841B1 (fr) 2014-12-01
SG10201510204QA (en) 2016-01-28
US20140350006A1 (en) 2014-11-27
KR20140105551A (ko) 2014-09-01
SG11201402851TA (en) 2014-07-30
KR102012058B1 (ko) 2019-08-19
EA201491149A1 (ru) 2014-11-28
EA027421B1 (ru) 2017-07-31
MX2014007168A (es) 2015-02-10
CN104114555B (zh) 2017-09-01

Similar Documents

Publication Publication Date Title
BR112014014452A2 (pt) derivados de pirazolpiridina, processo de preparação dos mesmos e uso terapêutico dos mesmos
ECSP14006132A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
BR112015022191A8 (pt) compostos heteroarila e usos dos mesmos
BR112014010183B8 (pt) Composto, composição farmacêutica, produto, e, uso de um composto
BR112014010206B8 (pt) composto derivado de piridopirazina, composição farmacêutica, e, uso de um composto
BR112014016165A8 (pt) compostos de benzaldeído substituído e métodos para seu uso no aumento da oxigenação do tecido
CY1118721T1 (el) Παραγωγα 2,3 διϋδρο-1η-ινδεν-1-υλ-2,7-διαζασπειρο[3.6]εννεανιου και η χρηση αυτων ως ανταγωνιστες ή αντιστροφοι αγωνιστες του υποδοχεα γκρελινης
BR112015010360A8 (pt) antagonistas de il-6 e utilização dos mesmos.
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
BR112015014458A2 (pt) derivados de manose para o tratamento de infecções bacterianas
BR112014011162A2 (pt) derivados purínicos para o tratamento de infecções virais
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
BR112015021027A2 (pt) compostos terapêuticos
CO6640270A2 (es) Morfolinopirimidad y su uso en terapia
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR112014029706A8 (pt) Composto, composição farmacêutica, e, uso de um composto
EA201591195A1 (ru) Новые хинолоновые производные
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
DOP2014000059A (es) Derivados de estra–1,3,5(10),16–tetraen–3–carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
BRPI1007092B8 (pt) Derivados de hidroxamato, uso dos derivados de hidroxamato, composições farmacêuticas e método de produção de derivados de hidroxamato
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
EA201600434A1 (ru) Применение производных бензимидазолпролина
BR112015023878A2 (pt) composto, composição farmacêutica, e, uso de um composto
EA201890532A1 (ru) Новые аннелированные бензамиды
BR112013030391A2 (pt) derivados de piperidina 3- espirocíclicos como agonistas dos receptores de grelina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]